ALBO - Albireo reports expanded data on Bylvay and A3907 at EASL international liver congress

Albireo Pharma (ALBO) presents new data showing efficacy and tolerability of Bylvay (odevixibat), as well as advancement in the characterization of A3907 in adult liver disease at EASL International Liver Congress 2021 on June 23 – 26.Highlights from the Phase 3 PEDFIC studies show further evidence of a sustained and durable effect of Bylvay in reducing pruritus and serum bile acids (sBAs), while also showing improvements in sleep, growth and hepatic parameters in patients with progressive familial intrahepatic cholestasis ((PFIC)). Key findings include: At baseline, sBAs score was 250 ?mol/L and pruritus score was 2.9. Four weeks after starting Bylvay, sBAs had decreased by 88 ?mol/L and pruritus score decreased by 0.7.At the end of the analysis period, sBAs had decreased from baseline by 213 ?mol/L in patients with available data and pruritus score dropped by 1.4.Height Z scores increased from –1.9 at baseline to –0.8 at week?48 and similar

For further details see:

Albireo reports expanded data on Bylvay and A3907 at EASL international liver congress